Abstract：
BACKGROUND: Plasma amyloid-β (Aβ), phosphorylated tau-181 (p-tau181), neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) potentially aid in the diagnosis of neurodegenerative dementias. We aim to conduct a comprehensive comparison between different biomarkers and their combination, which is lacking, in a multicenter Chinese dementia cohort consisting of Alzheimer\'s disease (AD), frontotemporal dementia (FTD), and progressive supranuclear palsy (PSP).
METHODS: We enrolled 92 demented patients [64 AD, 16 FTD, and 12 PSP with dementia] and 20 healthy controls (HC). Their plasma Αβ, p-tau181, NfL, and GFAP were detected by highly sensitive-single molecule immunoassays. Αβ pathology in patients was measured by cerebrospinal fluid or/and amyloid positron emission tomography.
RESULTS: All plasma biomarkers tested were significantly altered in dementia patients compared with HC, especially Aβ42/Aβ40 and NfL showed significant performance in distinguishing AD from HC. A combination of plasma Aβ42/Aβ40, p-tau181, NfL, and GFAP could discriminate FTD or PSP well from HC and was able to distinguish AD and non-AD (FTD/PSP).
CONCLUSIONS: Our results confirmed the diagnostic performance of individual plasma biomarkers Aβ42/Aβ40, p-tau181, NfL, and GFAP in Chinese dementia patients and noted that a combination of these biomarkers may be more accurate in identifying FTD/PSP patients and distinguishing AD from non-AD dementia.
METHODS: We enrolled 92 demented patients [64 AD, 16 FTD, and 12 PSP with dementia] and 20 healthy controls (HC). Their plasma Αβ, p-tau181, NfL, and GFAP were detected by highly sensitive-single molecule immunoassays. Αβ pathology in patients was measured by cerebrospinal fluid or/and amyloid positron emission tomography.
RESULTS: All plasma biomarkers tested were significantly altered in dementia patients compared with HC, especially Aβ42/Aβ40 and NfL showed significant performance in distinguishing AD from HC. A combination of plasma Aβ42/Aβ40, p-tau181, NfL, and GFAP could discriminate FTD or PSP well from HC and was able to distinguish AD and non-AD (FTD/PSP).
CONCLUSIONS: Our results confirmed the diagnostic performance of individual plasma biomarkers Aβ42/Aβ40, p-tau181, NfL, and GFAP in Chinese dementia patients and noted that a combination of these biomarkers may be more accurate in identifying FTD/PSP patients and distinguishing AD from non-AD dementia.
摘要：
背景：血浆淀粉样β（Aβ），磷酸化tau-181（p-tau181），神经丝光（NfL）和神经胶质纤维酸性蛋白（GFAP）可能有助于神经退行性痴呆的诊断。我们的目标是在不同的生物标志物及其组合之间进行综合比较，这是缺乏的，在由阿尔茨海默病(AD)组成的多中心中国痴呆队列中，额颞叶痴呆(FTD),和进行性核上性麻痹（PSP）。
方法：我们招募了92名痴呆患者[64名AD，16FTD,和12PSP与痴呆]和20健康对照（HC）。他们的血浆Αβ，p-tau181,NFL,和GFAP通过高度敏感的单分子免疫测定法检测。通过脑脊液或/和淀粉样蛋白正电子发射断层扫描测量患者的Αβ病理。
结果：与HC相比，痴呆患者的所有血浆生物标志物均发生了显着改变，特别是Aβ42/Aβ40和NfL在区分AD和HC方面表现出显著的性能。血浆Aβ42/Aβ40，p-tau181，NfL，GFAP可以很好地将FTD或PSP与HC区分开，并且能够区分AD和非AD（FTD/PSP）。
结论：我们的结果证实了单个血浆生物标志物Aβ42/Aβ40，p-tau181，NfL，和中国痴呆患者的GFAP，并指出这些生物标志物的组合可能更准确地识别FTD/PSP患者和区分AD和非AD痴呆。
方法：我们招募了92名痴呆患者[64名AD，16FTD,和12PSP与痴呆]和20健康对照（HC）。他们的血浆Αβ，p-tau181,NFL,和GFAP通过高度敏感的单分子免疫测定法检测。通过脑脊液或/和淀粉样蛋白正电子发射断层扫描测量患者的Αβ病理。
结果：与HC相比，痴呆患者的所有血浆生物标志物均发生了显着改变，特别是Aβ42/Aβ40和NfL在区分AD和HC方面表现出显著的性能。血浆Aβ42/Aβ40，p-tau181，NfL，GFAP可以很好地将FTD或PSP与HC区分开，并且能够区分AD和非AD（FTD/PSP）。
结论：我们的结果证实了单个血浆生物标志物Aβ42/Aβ40，p-tau181，NfL，和中国痴呆患者的GFAP，并指出这些生物标志物的组合可能更准确地识别FTD/PSP患者和区分AD和非AD痴呆。
